Effects of CpG Methylation on Recognition of DNA by the Tumour Suppressor p53

被引:16
|
作者
Petrovich, Miriana [2 ]
Veprintsev, Dmitry B. [1 ]
机构
[1] Mol Biol Lab, MRC, Cambridge CB2 0QH, England
[2] Ctr Prot Engn, MRC, Cambridge CB2 0QH, England
基金
英国医学研究理事会;
关键词
p53; DNA methylation; DNA binding; fluorescence anisotropy; CpG; FACTOR-BINDING-SITES; TRANSCRIPTION-FACTOR; P53-BINDING SITES; HUMAN GENOME; CORE DOMAIN; MUTANT P53; GENE; PROMOTER; PATTERNS; MAP;
D O I
10.1016/j.jmb.2008.11.054
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Methylation of DNA is one of the mechanisms controlling the expression landscape of the genome. Its pattern is altered in cancer and often results in the hypermethylation of the promoter regions and abnormal expression of tumour suppressor genes. Methylation of CpG dinucleotides located in the binding sites of transcription factors may contribute to the development of cancers by preventing their binding or altering their specificity. We studied the effects of CpG methylation on DNA recognition by the tumour suppressor p53, a transcription factor involved in the response to carcinogenic stress. p53 recognises a large number of DNA sequences, many of which contain CpG dinucleotides. We systematically substituted a CPG dinucleotide at each position in the consensus p53 DNA binding sequence and identified substitutions tolerated by p53. We compared the binding affinities of methylated versus non-methylated sequences by fluorescence anisotropy titration. We found that binding of p53 was not affected by cytosine methylation in a majority of cases. However, for a few sequences containing multiple CpG dinucleotides, such as sites in the RB and Met genes, methylation resulted in a four- to sixfold increase in binding of p53. This approach can be used to quantify the effects of CpG methylation on the DNA recognition by other DNA-binding proteins. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:72 / 80
页数:9
相关论文
共 50 条
  • [31] Ancient brothers of the human p53 tumour suppressor
    Brazda, V.
    Bartas, M.
    Cerven, J.
    Pecinka, P.
    FEBS OPEN BIO, 2021, 11 : 91 - 91
  • [32] p53: the tumour suppressor turns mitochondrial regulator
    Bartlett, Jonathan D.
    Morton, James P.
    JOURNAL OF PHYSIOLOGY-LONDON, 2013, 591 (14): : 3455 - 3456
  • [33] P53 tumour suppressor gene expression in hyperparathyroidism
    Subramaniam, P
    Wilkinson, S
    Shepherd, JJ
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 1996, 66 (05): : 302 - 304
  • [34] Activation and activities of the p53 tumour suppressor protein
    Bálint, É
    Vousden, KH
    BRITISH JOURNAL OF CANCER, 2001, 85 (12) : 1813 - 1823
  • [35] A microRNA component of the p53 tumour suppressor network
    Lin He
    Xingyue He
    Lee P. Lim
    Elisa de Stanchina
    Zhenyu Xuan
    Yu Liang
    Wen Xue
    Lars Zender
    Jill Magnus
    Dana Ridzon
    Aimee L. Jackson
    Peter S. Linsley
    Caifu Chen
    Scott W. Lowe
    Michele A. Cleary
    Gregory J. Hannon
    Nature, 2007, 447 : 1130 - 1134
  • [36] Is tumour suppressor gene p53 involved in neuroendocrine tumour carcinogenesis?
    Pavelic, K
    JOURNAL OF PATHOLOGY, 1996, 178 (03): : 359 - 359
  • [37] Pharmacological restoration and promotion of p53 tumour suppressor activity
    Foster, B
    Rastinejad, F
    BRITISH JOURNAL OF CANCER, 2002, 86 : S11 - S11
  • [38] p53 tumour suppressor: Structure, function-rescue
    Fersht, Alan
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2007, 24 (06): : 640 - 640
  • [39] The subcellular distribution of the p53 tumour suppressor, and organismal ageing
    Wesierska-Gadek, J
    Schmid, G
    CELLULAR & MOLECULAR BIOLOGY LETTERS, 2005, 10 (03) : 439 - 453
  • [40] Correlation of tumour suppressor gene p53 expression with pathohistological tumour characteristics
    Petrovic, Dusica
    Mitrovic, Slobodanka
    Knezevic, Milan
    Azanjac, Goran
    Tanaskovic, Irena
    Radovanovic, Dragce
    Preljevic, Ibrahim
    Stankovic, Vesna
    HEALTHMED, 2012, 6 (01): : 156 - 163